As is customary this month’s report focuses on deals with disclosed financial terms. Acquisitions continued to form a high proportion of the deals reported; nine out of the top 20 deals reported this month.
This follows on from the trend seen in the first half of 2013 with $29bn of M&A transactions in the first six months, putting 2013 on track to be the best year since 2010, according to Evaluate’s Pharma Half-Year Review 2013.
This month’s deals have strong international and regional flavours, with deals involving companies in across Europe, Africa, South America, US and Asia.
Oncology and rheumatoid arthritis (RA) deals dominated with a total of seven in the top 20 deals with a mix of product and platform technologies, as Big Pharma companies continued their quest to fill pipelines and stay ahead of the competition, but biotechs and mid-sized companies were also active